RE:RE:"We are very pleased with the enrollment rate..." It's not relevant. What's relevant is the fact we all know the study is waaaay of track and the reason is because the CEO only has 6 locations across 2 countries. That's a needle in a haystack on steroids. He took a trial halfway around the world to save a couple of dollars in the grand scheme of things. Contrast that with Bells Health the CeO likes to spout about. They have north of 100 clinical sites across North America. That's being serious and competent about meeting timelines you are spouting off about to the market and showing real leadership at getting to the most important thing for why you should exist as a clinical stage biotech company. That's days readouts with the hope of commercialization. Not running your mouth like a heavy rotation commercial. Over a year to get to 14 patients. On pace for 2 patients a month. Which leaves another 6 months for full enrollment and a data readout next year. Meanwhile, the company has scrapped all the original pipeline goals (NASH, IBD...) and turned to Zillion to 1 odds Cancer and psycho drug to rewire the brain of stroke victims. Yeah, that last one is truly a Man on Mars in our lifetime odds. But hey, there's nothing like a good bedtime story and Moreau is just the guy to do that kind of work. He def got all the story he could get out of COVID-19. Mackie Research told the end of the story 3 months ago. There was no statistical significance coming from the Phase 2b trial. That should have been the end of the story but the CEO kept it going for months on end to it's bitter end. End of story. BB